Dupixent receives FDA approval for treatment of moderate-to-severe asthma
Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving it as an add-on maintenance therapy for two specific types of asthma. This latest approval marks a pivotal advancement for patients with moderate-to-severe asthma. New FDA Approval for Dupixent: Key Details The FDA’s green light […]